Abstract

BackgroundNumerous studies have shown that Id-1 (Inhibitor of differentiation 1) is upregulated in several cancers and associated with tumor malignant characters. However, the clinical significance and biological role of Id-1 in non-small cell lung cancer (NSCLC) remains unclear.MethodsWe used RT-PCR, Western blot and Immunohistochemistry to measure Id-1 expression in NSCLC tissues and matched adjacent noncancerous tissues. The expression pattern of Id-1 in NSCLC tissues was determined by scoring system of immunohistochemical analysis. The Kaplan-Meier method was used to calculate the survival curve, and log-rank test to determine statistical significance. The Id-1 gene was overexpressed or downreuglated with Lentiviral vectors in NSCLC cells. And, the migration ability of NSCLC cells was tested in a Transwell Boyden Chamber.ResultsWe found that Id-1 is generally expressed higher in NSCLC tissues compared with matched adjacent noncancerous tissues. We also found that high Id-1 expression in tumor tissues is significantly correlated with tumor progression and poor survival in NSCLC patients. Furthermore, our experimental data revealed that knockdown of Id-1 significantly suppressed the proliferation, migration and invasion of NSCLC cells, whereas ectopic expression of Id-1 promoted the malignant phenotype of NSCLC cells. Mechanistic study showed that NF-κB signaling pathway contributed to the effects of Id-1 in NSCLC cells. Moreover, blocking the NF-κB pathway significantly inhibited the tumor-promoting actions of Id-1 in NSCLC cells.ConclusionsWe identified a tumorigenic role of Id-1 in NSCLC and provided a novel therapeutic target for NSCLC patients.

Highlights

  • Lung cancer, predominantly non-small cell lung cancer (NSCLC) is the most commonly diagnosed malignancy, accounting for ~20% of all cancer-related death worldwide [26]

  • Inhibitor of differentiation 1 (Id-1) is upregulated in tumor tissues and closely correlated with clinical outcomes of patients with NSCLC To investigate the potential role of Id-1 in NSCLC development, we firstly measured the expression of Id-1 in paired tumor tissues and matched adjacent noncancerous tissues from 96 patients with NSCLC using qRTPCR

  • The results showed that the expression of Id-1 protein was enhanced in NSCLC tissues in comparison with the adjacent noncancerous tissues by western blot assay (Fig. 1b)

Read more

Summary

Introduction

Predominantly non-small cell lung cancer (NSCLC) is the most commonly diagnosed malignancy, accounting for ~20% of all cancer-related death worldwide [26]. While remarkable progress during the past decades in diagnose and treatment of NSCLC, but the predicted 5-year survival rate is only around 15% [7]. It is mainly a consequence of regional recurrence and lymph node metastasis [2, 12]. For. Numerous studies have shown that Id-1 (Inhibitor of differentiation 1) is upregulated in several cancers and associated with tumor malignant characters. The clinical significance and biological role of Id-1 in non-small cell lung cancer (NSCLC) remains unclear

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call